INTRODUCTION {#S1}
============

The arcuate nucleus in the hypothalamus is critical for regulating whole-body metabolic homeostasis ([@R2]; [@R6]). The agouti-related protein (AgRP) and neuropeptide Y (NPY), which are synthesized and secreted from AgRP/NPY neurons, are two anabolic neuropeptides that stimulate food intake and decrease energy expenditure. Increased hypothalamic NPY levels in rats lead to hyperphagia and obesity ([@R41]), whereas loss of the *Npy* gene attenuates the obesity syndrome in *ob/ob* mice ([@R10]). Conversely, melanocortins, such as a-melanocyte-stimulating hormone (α-MSH) synthesized by proopiomelanocortin (POMC) neurons, inhibit food intake and promote energy expenditure ([@R11]). Mice lacking the melanocortin receptor MC4R are hyperphagic and severely obese, suggesting the importance of melanocortin signaling in the control of energy homeostasis ([@R15]).

Recent studies have demonstrated the importance of metabolic interaction between neurons and other cell types, such as astrocytes([@R12]; [@R17]), microglia ([@R35]; [@R42]), and tanycytes ([@R1]; [@R14]) in the regulation of energy homeostasis. Oligodendrocytes have also been suggested to be involved in metabolic homeostasis ([@R34]). Lack of proliferative oligodendrocyte precursor cells (OPCs) in the median eminence impairs hypothalamic leptin sensing and leads to weight gain in mice ([@R8]). Oligodendrocytes provide pyruvate and lactate to ensheathed neurons to maintain the integrity and normal neuronal functions ([@R20]; [@R32]), but the mechanisms underlying oligodendrocyte regulation of energy metabolic homeostasis remain elusive.

GPR17, a G-protein coupled receptor (GPCR) coupled to the Gi subunit, is predominantly restricted to the oligodendrocyte lineage. It is crucial for the timing of oligodendrocyte myelination ([@R5]). Overexpression of *Gpr17* inhibits myelin sheath development, whereas loss of *Gpr17* accelerates it and promotes remyelination upon injury ([@R5]; [@R28]). Recent studies suggest that GPR17 might also be involved in the regulation of whole-body energy homeostasis. In experiments in mice, administration of the GPR17 antagonist cangrelor reduced food intake, whereas the GPR17 agonist LTD4 induced food intake ([@R30]). Moreover, mice with *Agrp-cre-*mediated depletion of GPR17 are leaner than wild-type (WT) mice ([@R31]). In contrast, [@R25] reported that whole-body *Gpr17* knockout mice (*Gpr17*^−/−^) did not differ from WT mice in food consumption, glucose homeostasis, or energy expenditure when fed either standard chow or a high-fat diet (HFD) for 10 weeks. Therefore, whether and how GPR17 is involved in the regulation of energy homeostasis remains debated.

In this study, we used multiple approaches and animal models to investigate the effect of oligodendrocytes and GPR17 on energy homeostasis in mice. By analysis of mice that express GFP knocked in at the *Gpr17* locus, we showed that this gene is specifically expressed in oligodendrocyte lineage cells but hardly detectable in neurons. Both whole-body and oligodendrocyte-specific *Gpr17* knockout mice gained less weight when chronically exposed to an HFD than WT mice. Mechanistically, loss of *Gpr17* in oligodendrocytes enhanced glycolysis and lactate production, which then activated AKT and STAT3 signaling in hypothalamic neurons, leading to reciprocal AgRP and POMC neuropeptide regulation, increased energy expenditure, and amelioration of HFD-induced obesity in mice. Our data confirm the important role of GPR17 in oligodendrocytes, but not in neurons, in metabolic control and also demonstrate that the GPR17/cyclic AMP (cAMP)/lactate signaling axis regulates the activities of hypothalamic neurons to maintain energy homeostasis.

RESULTS {#S2}
=======

Gpr17^−/−^ Mice Are Resistant to HFD-Induced Obesity {#S3}
----------------------------------------------------

To investigate the effect of GPR17 on energy homeostasis, *Gpr17*^−/−^ mice ([@R5]) and their WT littermates were fed a normal chow diet (NCD) or an HFD. On the NCD, the body weight of *Gpr17*^−/−^ mice did not differ from WT litter-mate controls ([Figure S1](#SD1){ref-type="supplementary-material"}). On the HFD, there was no significant difference in body weight between the two genotypes for the first 12 weeks, but after that, the body weight in *Gpr17*^−/−^ mice became lower than that of WT controls; the difference was statistically significant beginning at 16 weeks ([Figure 1A](#F1){ref-type="fig"}). When sacrificed after 28 weeks on the HFD, *Gpr17*^−/−^ mice had significantly less fat mass compared with WT mice ([Figure 1B](#F1){ref-type="fig"}). The serum levels of insulin and leptin were also significantly lower in *Gpr17*^−/−^ mice ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). H&E staining showed that adipocytes in the epididymal white adipose tissue (eWAT) of *Gpr17*^−/−^ mice were much smaller than those of WT mice ([Figures 1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}). Consistently, there was less lipid accumulation in brown adipose tissue (BAT) of *Gpr17*^−/−^ mice and improved hepatic steatosis compared with WT mice ([Figures 1E](#F1){ref-type="fig"}, [1G](#F1){ref-type="fig"}, and [1H](#F1){ref-type="fig"}). *Gpr17*^−/−^ mice showed improved capability for glucose clearance and increased insulin sensitivity relative to WT mice ([Figures 1I](#F1){ref-type="fig"} and [1J](#F1){ref-type="fig"}). As shown in [Figure 1K](#F1){ref-type="fig"}, *Gpr17*^−/−^ mice consumed less food than their WT counterparts in the dark phase. When normalized to lean mass, the levels of oxygen consumption, carbon dioxide production, heat production, and ambulatory activities were comparable between the two geno-types ([Figures 1L](#F1){ref-type="fig"}--[1O](#F1){ref-type="fig"}).

Mice Treated with a GPR17 Antagonist Are Resistant to HFD-Induced Obesity {#S4}
-------------------------------------------------------------------------

To confirm that GPR17 was required for weight gain on the HFD, WT mice were treated with pranlukast, a GPR17 antagonist that has been shown to effectively antagonize GPR17 biological functions ([@R28]). Pranlukast-treated WT mice gained less body weight on the HFD than untreated mice ([Figure S2A](#SD1){ref-type="supplementary-material"}). Pranlukast treatment also modestly decreased the levels of serum insulin, leptin, free fatty acids, and liver triglycerides ([Figures S2B](#SD1){ref-type="supplementary-material"}--[S2E](#SD1){ref-type="supplementary-material"}).

Mice Lacking GPR17 in the Oligodendrocyte Lineage Are Resistant to HFD-Induced Obesity {#S5}
--------------------------------------------------------------------------------------

*Gpr17* has been shown to be predominantly expressed in the oligodendrocyte lineage ([@R5]) but has also been reported in other cells types ([@R31]; [@R43]). We performed a study to characterize the expression pattern of *Gpr17* in the brain using *Gpr17*^−/−^ mice, in which the *Gpr17* gene was replaced by a nucleus-localized *GFP* gene ([@R5]). The majority of GFP-positive cells were oligodendrocytes in the corpus callosum, cortex, and hypothalamus arcuate nucleus area, as indicated by a series of oligodendrocyte lineage markers ([Figure 2A](#F2){ref-type="fig"}; [Figure S3A](#SD1){ref-type="supplementary-material"}). None of the GFP-positive cells expressed neuronal markers---e.g., NeuN or parvalbumin ([Figure 2A](#F2){ref-type="fig"}; [Figure S3B](#SD1){ref-type="supplementary-material"}) in the cortex that can express Olig2, and the GFP-positive cells did not overlap with AgRP or POMC expression ([Figure 2B](#F2){ref-type="fig"}; [Figure S3C](#SD1){ref-type="supplementary-material"}), indicating that parvalbumin, AgRP, or POMC neurons did not express *Gpr17*. In addition, no GFP-positive cells expressed Iba1 or glial gibrillary acidic protein (GFAP) ([Figure S3C](#SD1){ref-type="supplementary-material"}), suggesting that *Gpr17* is not expressed in microglia or astrocytes.

Given these results, we hypothesized that GPR17 produced in oligodendrocytes regulates whole-body metabolic homeostasis. To test this, we generated conditional *Gpr17* knockout mice (*Olig1*^*cre/+*^*;Gpr17*^*fl/fl*^, *Gpr17cKO*) in which *Gpr17* was specifically knocked out in the oligodendrocyte lineage by crossing the *Gpr17*^*fl/fl*^ and oligodendrocyte lineage-expressing *Olig1*^*cre/+*^ mouse strains ([@R22]; [@R37]). To show that Olig1-Cre depleted GPR17 in oligodendrocytes, *Olig1*^*cre/+*^ mice were crossed with *Gt(ROSA)26Sor*^*tm9(CAG-tdTomato)Hze*^ mice, and immunofluorescence analysis was performed to evaluate the expression of tdTomato. This experiment revealed that the Olig1-Cre recombinase targeted mostly oligodendrocyte lineage cells, which were positive for Olig2, CC1, and platelet-derived growth factor receptor a (PDGFRa) ([Figure 2C](#F2){ref-type="fig"}). tdTomato was completely undetectable in NeuN-positive neurons and in Iba1-positive microglia ([Figures 2C](#F2){ref-type="fig"}; [S3D](#SD1){ref-type="supplementary-material"}). Importantly, the Olig1-Cre recombinase did not target AgRP- or POMC-positive cells in the hypothalamic arcuate nucleus ([Figure 2D](#F2){ref-type="fig"}). Olig1-Cre recombinase expression was detected in a subset of astrocytes (GFAP-positive cells; [Figure S3D](#SD1){ref-type="supplementary-material"}), but it should have little or no effect on our analysis because we did not detect GFP expression in astrocytes in the *Gpr17* knockin experiment ([Figure S3C](#SD1){ref-type="supplementary-material"}). These data demonstrate that the *Gpr17cKO* mouse can be used to investigate the potential effect of *Gpr17* deletion, specifically in oligodendrocytes, on whole-body energy homeostasis.

When *Gpr17cKO* mice and their control littermates (*Gpr17*^*fl/fl*^) were fed the NCD, there were no obvious differences in body weight, fat mass, or lipid accumulation in tissues or metabolic parameters, including food intake, oxygen consumption, carbon dioxide production, heat production, or ambulatory activity ([Figure S4](#SD1){ref-type="supplementary-material"}). On the HFD, however, *Gpr17cKO* mice mirrored *Gpr17*^−/−^ mice. *Gpr17cKO* mice had lower body weight and less fat mass content than their control littermates after 16 weeks of HFD feeding ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). Serum levels of insulin and leptin were decreased in *Gpr17cKO* mice relative to controls ([Figures 3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}), and lipid accumulation in the liver, WAT, and BAT was also significantly lower in *Gpr17cKO* mice ([Figures 3E](#F3){ref-type="fig"}--[3H](#F3){ref-type="fig"}). Lack of GPR17 in oligodendrocytes also improved glucose tolerance and insulin sensitivity ([Figures 3I](#F3){ref-type="fig"} and [3J](#F3){ref-type="fig"}). Moreover, the metabolic cage data also revealed that *Gpr17cKO* mice had decreased food intake in the dark phase ([Figure 3K](#F3){ref-type="fig"}). When normalized to lean mass, *Gpr17cKO* mice had similar levels of oxygen consumption, carbon dioxide, heat production, and ambulatory activities as their control littermates ([Figures 3L](#F3){ref-type="fig"}--[3O](#F3){ref-type="fig"}).

Because we have previously reported that loss of *Gpr17* promotes precocious myelination and remyelination ([@R5]), we examined myelin sheaths in *Gpr17*^−/−^ mice fed an NCD or HFD and their control littermates. We found that the *g*-ratio and myelinated axon numbers were similar after 30 weeks of NCD feeding and after 60 weeks of HFD feeding ([Figure S5](#SD1){ref-type="supplementary-material"}). This suggests that myelination does not contribute to the lean phenotype of *Gpr17*^−/−^ mice.

A previous study by [@R25] showed that the expression of *Lims2* was decreased by 30% in their *Gpr17*-null mice relative to WT controls ([@R25]). This was likely due to the fact that the coding region of *Gpr17* is nested in the fourth intron of *Lims2* ([Figure S6C](#SD1){ref-type="supplementary-material"}). We then examined the expression of *Lims2* in the corpus callosum and hypothalamus in our *Gpr17*^−/−^ mice and their littermates. We found that the expression of *Lims2* was unaffected after *Gpr17* deletion ([Figure S6D](#SD1){ref-type="supplementary-material"}). Furthermore, there was no difference in the expression of *Lims2* between WT and *Gpr17*-deficient OPCs or mature oligodendrocytes (OLs; [Figure S6E](#SD1){ref-type="supplementary-material"}). These results suggest that *Lims2* expression is not the driving force behind the lean pheno-type in our *Gpr17*^−/−^ mice.

Loss of Gpr17 Promotes Lactate Production in OLs {#S6}
------------------------------------------------

Previous studies have shown that OLs can metabolically support ensheathed axons through secretion of metabolites, including lactate and pyruvate, which maintain axonal function and ensure neuronal survival ([@R20]; [@R32]). We hypothesized that depletion of GPR17 from OLs resulted in an altered metabolic signal from OLs to nearby neurons and, thus, led to changes in whole-body energy homeostasis.

To examine the effect of GPR17 on the metabolic profile of OLs, we isolated primary OPCs from WT and *Gpr17*^−/−^ mice and subjected these cells, before and after differentiation into OLs, to the Seahorse assay. GPR17-deficient OPCs displayed dramatically increased extracellular acidification rates (ECARs), a surrogate marker of glycolysis, compared with WT OPCs ([Figures 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}), suggesting increased glycolysis and lactate production in the absence of GPR17. To verify this, we directly measured lactate production by WT and GPR17-deficient OPCs because GPR17 is strongly expressed at the OPC and newly formed OL stages. We found a higher lactate concentration in medium collected from GPR17-deficient OPCs ([Figure 4C](#F4){ref-type="fig"}). Similar observations were made in OLs ([Figures 4D](#F4){ref-type="fig"}--[5F](#F5){ref-type="fig"}). Moreover, the oxygen consumption rates (OCRs) were similar in WT and GPR17-deficient OPCs and OLs ([Figure 4G](#F4){ref-type="fig"} and [4H](#F4){ref-type="fig"}), indicating that oxidative phosphorylation in mitochondria was unaffected by lack of GPR17. There was no difference in viability between GPR17-deficient and WT OPCs, as indicated by a CCK-8 cell viability assay ([Figure 4I](#F4){ref-type="fig"}) and by the lack of TdT-mediated dUTP nick-end labeling (TUNEL) staining (data not shown).

GPR17 Regulates Expression of PDK1 through cAMP and the Protein Kinase A Signaling Pathway {#S7}
------------------------------------------------------------------------------------------

We reasoned that the increase in lactate production in GPR17-deficient OLs could be due to decreased shuttling of pyruvate into the Krebs cycle. Consistent with this hypothesis, the level of the kinase PDK1 was much higher in GPR17-deficient OPCs and OLs than in controls, and phosphorylation of the E1a subunit of pyruvate dehydrogenase (PDH), a well-established substrate of PDK1, was increased in the GPR17-deficient OPCs and OLs ([Figure 5A](#F5){ref-type="fig"}). Furthermore, the level of *Pdk1* mRNA was also significantly higher in the GPR17-deficient OPCs and OLs than in controls (Figures [5B](#F5){ref-type="fig"}). In both NCD- and HFD-fed *Gpr17cKO* mice, the levels of PDK1 and phosphorylated PDH were significantly higher than those of WT mice ([Figure 5C](#F5){ref-type="fig"}).

Previous studies have demonstrated that expression of GPR17 results in activation of Gai, reducing the production of intracellular cAMP and, thus, inhibiting downstream signaling pathways involving cAMP, such as protein kinase A (PKA) signaling ([@R13]). Similar to what we reported pre viously for rat OPCs deficient in GPR17 ([@R28]), the cAMP levels were increased in both OPCs and OLs isolated from *Gpr17*^−/−^ mice compared with those in WT mice ([Figure 5D](#F5){ref-type="fig"}). As a result, the level of phosphorylated PKA was also significantly elevated ([Figure 5A](#F5){ref-type="fig"}).

To further confirm the requirement for PKA signaling in the glycolytic process in OL lineage cells, OPCs and OLs were treated with the PKA signaling activators dibutyl-cAMP and forskolin or the PKA inhibitor KT5720. Treatment of WT OPCs with0.5 mM dibutyl-cAMP or 10 μM forskolin increased the ECAR, indicating increased production of lactate ([Figures 5E](#F5){ref-type="fig"}, [5F](#F5){ref-type="fig"}, [S7A](#SD1){ref-type="supplementary-material"}, and [S7B](#SD1){ref-type="supplementary-material"}). Conversely, when PKA signaling was blocked by treatment of cells with 0.5 μM KT5720, the extracellular acidification level in GPR17-deficient OPCs declined ([Figures 5G](#F5){ref-type="fig"} and [S7C](#SD1){ref-type="supplementary-material"}). Similar results were obtained at the OL stage with the same treatments ([Figures 5H](#F5){ref-type="fig"}--[5J](#F5){ref-type="fig"} and [S7D](#SD1){ref-type="supplementary-material"}--[S7F](#SD1){ref-type="supplementary-material"}).

Consistent with the activation of PKA signaling, *c-Fos* expression was upregulated at both the mRNA and protein levels in *Gpr17*^−/−^ cells ([Figures 5K](#F5){ref-type="fig"} and [5L](#F5){ref-type="fig"}). When *c-Fos* was overex-pressed in OLN-93 cells, the expression of *Pdk1* increased about1.7-fold ([Figure 5M](#F5){ref-type="fig"}). A *c-Fos* response element was identified in the promoter region of the *Pdk1* gene, suggesting that *c-Fos* directly regulates its expression. To test this, we generated a reporter construct carrying the 1-kb proximal promoter of the *Pdk1* gene. When a *c-Fos*-expressing vector was co-transfected with this reporter, a 3.5-fold induction of the luciferase activity was observed. When the putative *c-Fos* response element was mutated, *c-Fos* no longer induced the expression of luciferase ([Figure 5N](#F5){ref-type="fig"}).

Increased Lactate Production in OLs Augments Neuronal AKT and STAT3 Signaling {#S8}
-----------------------------------------------------------------------------

We then sought to explore whether lactate influences AKT or STAT3 signaling pathways because activation of these pathways in AgRP/NPY and POMC neurons suppresses appetite and accelerates energy expenditure by reciprocally reducing the synthesis of AgRP/NPY peptides and increasing the synthesis of POMC peptide ([@R8]; [@R18]; [@R40]). We treated primary cultures of hypothalamic neurons from rats with lactate and found that the phosphorylated AKT and STAT3 levels were increased in a time-dependent manner ([Figure 6A](#F6){ref-type="fig"}). Because lactate is transferred from glial cells into the neuronal cytoplasm through monocarboxylate transporters (MCTs) ([@R20]; [@R29]), we treated cultures with α-cyano-4-hydroxycinnamic acid (4-CIN), a broad-spectrum MCT inhibitor. When the cells were treated with 4-CIN, lactate-mediated activation of AKT and STAT3 was largely blocked ([Figure 6B](#F6){ref-type="fig"}). Notably, when primary hypothalamic neurons were treated with lactate, there was increased expression level of *Pomc* and decreased expression level of *Agrp* ([Figure 6C](#F6){ref-type="fig"}), and these alterations in gene expression were not observed when cells were treated with both lactate and 4-CIN.

To confirm these results *in vivo*, we administered lactate into the third ventricle of WT mice through intracerebroventricular (i.c.v.) injection. Both phosphorylated AKT and STAT3 levels increased in a time- and dose-dependent manner after lactate injection ([Figures 6D](#F6){ref-type="fig"} and [6E](#F6){ref-type="fig"}). Lactate also induced the expression of *Pomc* and suppressed *Agrp* ([Figure 6F](#F6){ref-type="fig"}). Moreover, when the mice were pretreated with 4-CIN, lactate-induced changes in the levels of phosphorylated AKT and STAT3 were not observed ([Figure 6G](#F6){ref-type="fig"}). Physiologically, mice given lactate had reduced food intake relative to untreated mice. Although administration of 4-CIN only elicited a tendency toward increased food intake, which might be due to the complicated network of appetite control, pre-treatment with 4-CIN largely restored the lactate-suppressed appetite ([Figure 6H](#F6){ref-type="fig"}).

These results clearly demonstrated that excessive lactate activates neuronal AKT and STAT3 signaling pathways. Considering that *Gpr17*^−/−^ OLs produced more lactate than WT OLs ([Figure 4](#F4){ref-type="fig"}), we hypothesized that the elevated lactate in the environment of the hypothalamic neurons in *Gpr17cKO* mice might have the same effects on these signaling pathways. To test this hypothesis, we quantified lactate in the hypothalami of control *Gpr17*^*fl/fl*^ and *Gpr17cKO* mice. Consistent with the *in vitro* findings, loss of *Gpr17* increased the lactate concentration in the hypothalamus ([Figure 7A](#F7){ref-type="fig"}).

We then compared the hypothalamus samples from control and *Gpr17cKO* mice after 30 weeks on either the NCD or HFD and found that the levels of phosphorylated AKT and phosphorylated STAT3 were higher in the *Gpr17cKO* mice ([Figures 7B](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}). Immunofluorescence showed that the population of cells that were positive for both phosphorylated AKT and STAT3 were increased in the hypothalamus of HFD-fed *Gpr17cKO* relative to *Gpr17*^*fl/fl*^ mice ([Figure 7D](#F7){ref-type="fig"}). When the *Gpr17cKO* mice were treated with 4-CIN or oxamate, a lactate dehydrogenase (LDH) inhibitor, the levels of phosphorylated AKT and phosphorylated STAT3 were decreased concordantly in control *Gpr17*^*fl/fl*^ mice ([Figure 7E](#F7){ref-type="fig"}). Moreover, the levels of *Agrp* were decreased and the levels of *Pomc* were increased in HFD-fed *Gpr17cKO* mice relative to the HFD-fed controls ([Figure 7F](#F7){ref-type="fig"}). To further demonstrate the consequences of AKT and STAT3 activation in hypothalamic neurons, we the evaluated levels and localization of c-Fos, which serves as a surrogate indicator for neuron activities ([@R7]; [@R9]; [@R36]). As shown in [Figure 7G](#F7){ref-type="fig"}, compared with control mice, *Gpr17cKO* mice fed the HFD showed a dramatic upregulation of *c-Fos* expression in POMC neurons.

To further interrogate the effect of Gi-coupled GPR17 signaling activation in OLs on lactate production and hypothalamic neuronal responses, we utilized a chemogenetic DREADD (designer receptors exclusively activated by designer drugs) system ([@R45]) by breeding *Olig1*^*cre/+*^ mice with the *R26-LSL-Gi-DREADD* transgenic line to generate *Olig1*^*cre/+*^*; Gi-DREADD* mice. In these mice, expression of hM4Di, a mutant GPCR that activates the canonical Gi pathway upon treatment with clozapine-N-oxide (CNO) in OLs. CNO might exhibit some off-target effects ([@R23]; [@R24]). To minimize any potential non-specific effect of CNO, both *Gi-DREADD* and *Olig1*^*cre/+*^*;Gi-DREADD* mice were treated with CNO at post-natal day 12 (P12) with a dose of 1 mg/kg of body weight for 2 h, and then hypothalamus samples were harvested for analysis. The lactate content in the hypothalamus of *Olig1*^*cre/+*^;*Gi-DREADD* mice decreased by approximately 25% compared with that of vehicle-treated control mice ([Figure 7H](#F7){ref-type="fig"}). *In vitro*, OPCs isolated from *Olig1*^*cre/+*^*; Gi-DREADD* mice showed a lower lactate content compared with those from *Gi-DREADD* mice ([Figure 7I](#F7){ref-type="fig"}). In addition, CNO treatment resulted in a significant decrease in *Pomc* expression and a moderate increase in *Agrp* expression ([Figure 7J](#F7){ref-type="fig"}). These data indicate that activation of GPR17 signaling in OLs leads to reduced lactate production in the hypothalamus, leading to the alteration in *Agrp* and *Pomc* expression in neurons that eventually affects appetite.

DISCUSSION {#S9}
==========

GPR17-Mediated OL Activity Controls Metabolic Homeostasis {#S10}
---------------------------------------------------------

OLs have been implicated in the regulation of energy homeostasis, although the mechanisms were incompletely understood. A recent report indicated that depletion of NG2-positive glia resulted in increased food consumption and body weight in mice by impairing leptin sensing in the hypothalamus ([@R8]), suggesting a potential role of OL precursors in the regulation of metabolic homeostasis. Here we showed that *Gpr17*^−/−^ and *Gpr17cKO* mice are both resistant to HFD-induced obesity. Considering that GPR17 is primarily expressed in OLs and restricted to them among cells undergoing *Olig1*-promoter-driven ablation, we conclude that the GPR17 expressed by OLs regulates the activity of downstream effectors intercellularly to ultimately control energy metabolism through neurons.

[@R25] found that weight gain by *Gpr17*^−/−^ mice did not differ from that of WT mice fed on the NCD for 13 weeks and then the HFD for an additional 10 weeks. Consistent with this, we found that the weights of *Gpr17*^−/−^ mice did not differ from those of control littermates fed the NCD for up to 30 weeks or the HFD for 12 weeks. We continued to monitor body weight for 28 weeks on the HFD. From week 12, the body weight of *Gpr17*^−/−^ mice gradually fell behind that of their WT littermates, and the differences were statistically significant from week 16.

By generating OL-specific *Gpr17* knockout alleles, we found that *Gpr17cKO* mice exhibited lower body weights than WT littermate controls starting from week 16 on the HFD. In addition, treating WT mice with pranlukast, an antagonist of GPR17, slowed the gain in body weight of mice fed the HFD. Therefore, our data demonstrate that GPR17-mediated signaling modulates OL activity to control energy metabolism.

A previous study indicated that the expression of *Lims2* in a *Gpr17*^−/−^ mouse line was downregulated by approximately 30%, according to RNA sequencing fragments per kilobase of transcript per million fragments mapped (FPKM) data ([@R25]); however, this change was not confirmed by qRT-PCR analyses. In contrast, in our *Gpr17*^−/−^ mice, which were generated by removing the *Gpr17* coding exon without affecting *Lims2* exons, when measuring the *Lims2* mRNA level in brain tissues as well as isolated OPCs or OLs by qRT-PCR, we did not observe any significant difference between *Gpr17*^−/−^ mice and their control littermates. The exact mechanism behind the potential discrepancy between these *Gpr17*-null mice is not known; it is possible that the difference in the genetic knockout strategies or different genetic backgrounds may contribute to the changes in neighboring *Lims2* gene expression ([Figure S6A](#SD1){ref-type="supplementary-material"}). Nonetheless, the lack of significant alteration of *Lims2* expression suggests that Lims2 not likely to be the major factor contributing to the energy metabolism phenotype observed in our *Gpr17* knockout mice.

GPR17 Modulates Glycolysis and Lactate Productionin OLs {#S11}
-------------------------------------------------------

We showed that loss of *Gpr17* led to increased lactate production through the cAMP-PKA pathway. Consistent with our previous findings in rat OLs ([@R28]), loss of *Gpr17* in mouse OLs caused a significant increase in cellular cAMP levels and PKA activity, which, through c-Fos, upregulated *Pdk1* and, hence, increased phosphorylation of the E1α subunit of PDH. Both Seahorse analysis and direct measurements indicated that lactate production was significantly increased in *Gpr17*^−/−^ OLs both at the OPC and OL stages. Furthermore, the cAMP-elevating agent forskolin and the cAMP mimetic dibutyl (db)-cAMP both dramatically increased lactate production in OLs, suggesting that GPR17 regulates lactate production through cAMP-PKA signaling in OLs.

To show the hypothalamic specificity of the GPR17-cAMP-lactate axis, we found that i.c.v. injection of lactate activated AKT and STAT3 signaling, upregulated *Pomc*, and downregulated *Agrp*. Importantly, administration of 4-CIN prior to lactate injection almost completely blocked activation of these pathways and resulted in a normal appetite. Moreover, administration of 4-CIN and oxamate to the hypothalamus of NCD-fed *Gpr17cK*O mice significantly decreased AKT and STAT3 activation. Consistent with our findings, [@R8] reported that removal of NG2-positive OLs from the hypothalamus resulted in increased food intake and body weight gain ([@R8]). These results suggest that OLs in the hypothalamus play a role in the regulation of whole-body metabolism.

GPR17-Mediated Signaling Modulates Neuronal Activity through a Lactate Shuttle between OLs and Neurons {#S12}
------------------------------------------------------------------------------------------------------

Lactate has been reported previously to provide nutritional support to neurons ([@R33]) and has been shown to serve as a signal transmitter in the brain ([@R3]; [@R19]). Recent studies demonstrated that OLs provide pyruvate and lactate, necessary for normal function of ensheathed axons ([@R20]; [@R32]). Activation of the AKT and STAT3 pathways in the hypothalamus leads to increased *Pomc* but decreased *Agrp*, which then results in reduced appetite ([@R8]; [@R18]; [@R40]). In our studies, lactate treatment of primary cultured neurons caused increased phosphorylation of both AKT and STAT3, upregulated *Pomc*, and downregulated *Agrp*. Importantly, these effects of lactate were largely abolished by pretreatment with 4-CIN, a monocarboxylate transport inhibitor. Interestingly, injection of lactate into the third ventricle also caused increased levels of phosphorylated AKT (p-AKT) and p-STAT3. Furthermore, depletion of GPR17 in the OLs caused a dramatic increase in p-AKT and p-STAT3 in the hypothalamus and activation of anorexigenic POMC neurons with concomitant and reciprocal reduced activation of orexigenic AgRP neurons, which could explain the resistance of *Gpr17*^−/−^ and *Gpr17cKO* mice to HFD-induced obesity. Therefore, we hypothesize that the lactate produced by OLs functions as a metabolic signal to modulate hypothalamic neuronal activity. Consistent with this hypothesis, lactate has been reported to increase the action potential frequency of the glucose-excited neurons in the ventromedial nucleus (VMH) area ([@R39]). Although we showed that lactate activates AKT and STAT3 signaling pathways through MCTs to regulate the expression of *Pomc* and *Agrp*, the molecular mechanism by which lactate acts remains to be determined.

The Regulatory Effect of GPR17 on Energy Homeostasis Acts through OLs {#S13}
---------------------------------------------------------------------

Our studies clarified the effect of GPR17 on the regulation of energy metabolism upstream of lactate secretion by way of OLs. Using agonists and antagonists of GPR17, [@R31] showed that GPR17 is positively related to food intake and showed that, when *Gpr17* was knocked out in AgRP neurons, mice were resistant to weight gain. Our previous studies ([@R5]; [@R28]) and the current data ([Figures 2](#F2){ref-type="fig"} and [S3](#SD1){ref-type="supplementary-material"}) indicate that *Gpr17* is specifically expressed in the OL lineage (Olig2^+^, PDGFRα^+^, NG2^+^, CC1^+^, proteolipid protein \[PLP\]^+^, and myelin basic protein \[MBP\]^+^) but not in GFAP^+^ astrocytes, NeuN^+^ neurons, or Iba1^+^ microglia. When fed with an HFD, *Gpr17*^−/−^ mice were less obese compared with control WT mice, showing improved capacity for glucose clearance and increased insulin sensitivity. In addition, *Gpr17*^−/−^ mice exhibited reduced food intake. Moreover, the reduced obesity in *Gpr17*^−/−^ mice can be recapitulated in *Gpr17cKO* mice in terms of HFD effects. These observations suggest a specific role of oligodendrocytic GPR17 in mediating the protection of diet-induced obesity (DIO).

It is worth noting that the *Agrp-cre* line used by [@R31] often mimics germline deletion ([@R16]; [@R26]). It is therefore possible that the *Gpr17* deletion driven by *Agrp-cre* could potentially take place in OL lineage cells, leading to the phenotypes observed in our OL-specific *Gpr17* knockout mice.

Collectively, based on the data described here and previous research, we suggest that loss of GPR17 function increases cellular cAMP levels and activates PKA signaling, which upregulates the expression of *c-Fos* and *Pdk1*, leading to elevated lactate production. Lactate released from GPR17-deficient OLs enters nearby neuropeptidergic hypothalamic neurons to regulate metabolism and food intake. Thus, the cascade initiated by loss of GPR17 in OLs regulates whole-body metabolic homeostasis. Our finding that GPR17 signaling in OLs regulates food intake and appetite by modulating neuronal activities in the hypothalamus suggests that modulation of GPR17 signaling might be a potential therapeutic avenue for treating obesity.

STAR⋆METHODS {#S14}
============

CONTACT FOR REAGENT OR RESOURCE SHARING {#S16}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ying Chen (<yingchen@xmu.edu.cn>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S17}
--------------------------------------

### Animals {#S18}

*Gpr17*^−/−^ mice were generated as described previously ([@R5]). The *Gpr17* ^*fl/fl*^ and *Olig1-Cre* mice were generated as previously described ([@R28]; [@R37]). The *Gt(ROSA)26Sor*^*tm9(CAG-tdTomato)Hze*^ mice were kindly provided by Dr. Liang Zhang (Xiamen University). The *Gt(ROSA)26Sor*^*tm1(CAG-CHRM4\*,-mCitrine)Ute*^*/J* mice were purchased from the Jackson laboratory (Cat^\#^ 026219) and were genotyped according to the protocol from the Jackson laboratory. C57BL/6 mice and Sprague-Dawley rats were purchased from and maintained in the Xiamen University Laboratory Animal Center. All mice were maintained in the Xiamen University Laboratory Animal Center. Male mice were used in the study, and littermates were used as controls. *Gpr17*^−/−^ mice and *Gpr17cKO* mice were subjected to HFD feeding at 4 and 8 weeks of age, respectively. Mice at P7-P8 were used to collect OPCs for the primary culture. Rats at P0 were used to collect hypothalamus neurons for the primary culture. All of the animal experiments were approved by and performed according to the experimental guidelines of the Animal Care and Use Committee of Xiamen University.

METHOD DETAILS {#S19}
--------------

### Metabolic cage analysis {#S20}

Both HFD-treated *Gpr17*^−/−^ and *Gpr17cKO* mice were subjected to metabolic cage analysis after 26 weeks of feeding, and NCD-fed *Gpr17cKO* mice were subjected to analysis at 31 weeks of age. Metabolic parameters were measured using a TSE Labmaster Platform (TSE System). Cages were maintained at 20--22°C under a 12:12 h light-dark cycle (light period 07:00--19:00). Mice were singly housed for 5 days and were allowed to acclimatize to the TSE metabolic cages 3 days before metabolic experiments.

### Glucose tolerance test (GTT) and insulin tolerance test (ITT) {#S21}

Both HFD-treated *Gpr17*^−/−^ and *Gpr17cKO* mice were subjected to GTT after 24 weeks of HFD-feeding and to ITT after 25 weeks of HFD-feeding. For GTT, food was removed 16 h prior to assay from 17:00 to 09:00. Mice received intraperitoneal injections (i.p.) of D-glucose (2 g/kg, Sigma). For ITT, mice were fasted for 4 h from 09:00 to 13:00 followed by i.p. injections of insulin (0.5 units/kg). Blood glucose concentrations from tail vein were measured at the indicated time points using a glucometer (Sinocare, Inc.).

### Serum components and liver triglyceride analysis {#S22}

Mice serum samples were collected from eyeballs and clotted for 30 min at room temperature before centrifuging at 3000 *g* for 10 min. Serum levels of insulin and leptin were determined using enzyme immunoassay kits from Millipore and R&D Systems, respectively, according to the manufacturers' instructions. Serum-free fatty acid levels were determined by the ACS-ACOD method (Wako, Cat^\#^ 294--63601). Liver triglyceride was extracted by trichloromethane, and measured using a Triglyceride Assay Kit by the GPODAOS method as suggested by the manufacturer (Wako, Cat^\#^ 290--63701).

### H&E Staining {#S23}

After deparaffinization and rehydration, 6-mm sections were stained with hematoxylin solution (Sigma Cat^\#^ HHS16) for 8 min and rinsed in distilled water for 3 min. Then the sections were stained with eosin solution (Sigma Cat^\#^ HT110316) for 2 min and followed by dehydration with graded alcohol and clearing in xylene. The mounted slides were then examined and photographed using an Olympus BX53 microscope. The lipid droplet-positive areas of WAT, BAT, and liver were calculated by ImageJ software.

### Electron microscopy {#S24}

The corpus callosum regions from *Gpr17*^−/−^ mice and their control littermates, with either 30 weeks of NCD feeding or 60 weeks of HFD feeding were dissected and fixed in a solution of 4% paraformaldehyde, pH 7.4, 2.5% glutaraldehyde, and 0.08 M sodium cacodylate, pH 7.4. The ultrathin sections were investigated under a Transmission Electron Microscope (TEM) (Hitachi HT-7800). A total number of 20 fields per section were randomly chosen and photographed at a magnification of X2000. The percentages of the myelinated axons and the G ratio (the ratio between the axonal diameter and the fibers diameter) were quantified.

### Mouse OL primary culture {#S25}

Mouse cortices were isolated from postnatal day 7 to 8 mouse as described previously ([@R4]) with slight modifications. Briefly, Cortical tissues were diced thoroughly (\~1 mm^3^ pieces) and transferred into 20 units/ml papain buffer (Worthington, Cat^\#^ 3126) to digest for 45 min. After digestion, tissues were dispersed into single cells in an ovomucoid trypsin inhibitor buffer (Worthington, Cat^\#^ A003085). The cell suspension was then subjected to immunopanning with antibodies against GalC and O4 sequentially. The enriched Galc-negative O4-positive OPCs were plated into PDL-coated culture dishes and culture with OPC growth medium. OPC growth medium was DMEM/F-12 (GIBCO, Cat^\#^ 11330--032) containing 1% N2 supplement (GIBCO Cat^\#^ A1370701), 2% B27 supplement (GIBCO Cat^\#^ A3582801), penicillin-streptomycin solution (MP Biomedicals Cat^\#^ 0916700), 1% sodium pyruvate (GIBCO Cat^\#^ 11360070), 1% L-glutamine (Hyclone Cat^\#^ SH30034), 10 ng/ml platelet-derived growth factor-aa (Peprotech Cat^\#^ 100--13A), 10 ng/ml ciliary neurotrophic factor (Peprotech Cat^\#^ 450--13), 20 ng/ml human basic fibroblast growth factor (Sino Biological Cat^\#^ 10014HNAE), 0.5 mg/ml insulin (Sigma Cat^\#^ 91077), 5 mg/ml N-acetyl cysteine (Sigma Cat^\#^ A8199), 10 ng/ml D-biotin (Sigma Cat^\#^ B4639), 5 mM forskolin (Sigma Cat^\#^ F3917), 0.1% Trace Elements B (Corning Cat^\#^ 25--022-CI). OPC differentiation medium contained the same components above except that 40 ng/ml triiodo-thyronine (Sigma Cat^\#^ T2877) without human basic fibro-blast growth factor and platelet-derived growth factor-aa as previously described ([@R44]).

### Hypothalamic neuron primary culture {#S26}

A mixed primary culture of hypothalamic neurons and glia were prepared from Sprague-Dawley rats pups at P0 and maintained in culture at 37°C and 5% CO~2~ as previously described ([@R21]) with slight modifications. Briefly, the hypothalamic region of the brain was dissected in ice cold HBSS (HyClone Cat^\#^ SH30268.01) containing penicillin-streptomycin solution (MP Biomedicals Cat^\#^ 0916700) and sodium pyruvate (GIBCO Cat^\#^ 11360070), and was subjected to enzymatic desegregation for 20 min at 37°C in papain buffer containing 20 units/ml papain (Worthington Cat^\#^ 3126) and 250 units/ml DNaseI (Worthington Cat^\#^ 2006). The tissue was then mechanically disaggregated into isolated cells in a Neurobasal medium (GIBCO Cat^\#^ A1371201) with 5% (v/v) horse serum (GIBCO Cat^\#^ 26050088), Glutamax-I (GIBCO Cat^\#^ 35050--061), B27 supplement (GIBCO Cat^\#^ A3582801), and 250 units/ml DNaseI. The cells (1.0 × 10^6^ cells/cm^2^) were plated in wells of 6-well plates that were coated with 0.1 mg/mL poly-D-lysine (Sigma-Aldrich Cat^\#^ P7280). After 2 h, medium was replaced with Neurobasal medium supplemented with B27, Glutamax-I, and penicillin-streptomycin solution. The medium was replaced every 3 days, and the cells were maintained in culture for 5--7 days.

### Immunohistology {#S27}

Mice were anesthetized by chloral hydrate and perfused with 4% paraformaldehyde (PFA). Tissues were post-fixed overnight in 4% PFA, transferred to 30% sucrose, and 30-μm frozen sections were prepared. The sections were incubated in blocking solution (0.4% Triton X-100, 3% BSA in PBS) for 1 h at room temperature. In the case of POMC staining, the sections were pretreated with0.5% Triton X-100, 0.5% H~2~O~2~. Primary antibodies were then applied overnight at 4°C. The next day, sections were washed three times (5 min each time) in PBS and incubated with the secondary antibodies for 2 h at room temperature.

### Real-time quantitative PCR {#S28}

Total cellular RNAs were extracted using TRIzol (Takara Cat^\#^ 9109) according to the manufacturer's instructions, and RNA purity was confirmed by analysis of the ratio of absorbance at 260 nm to that at 280 nm absorption. cDNAs were prepared from 1 g total RNAs using Hifair™ II 1st Strand cDNA Synthesis SuperMix for qPCR (Yeasen Cat^\#^ 11123ES60) according to the manufacturer's instructions. Quantitative PCRs were performed using Hieff™ qPCR SYBR Green Master Mix (Yeasen Cat^\#^ 11201ES08). The primers used were as follows (5′-3′): Mouse primers: *GAPDH* (forward: AACAGCAACTCCCACTCTTC; reverse: CCTGTTGCTGTAGCCGTATT), *AgRP* (forward: TGTGTAAGGCTGCACGAGTC; reverse: ATTGAAGAAGCGGCAGTAGC), *POMC* (forward: GCTTGCAAACTCGA CCTCTC; reverse: GTACTTCCGGGGGTTTTCAG), *PDK1* (forward: GGACTTCGGGTCAGTGAATGC; reverse: TCCTGAGAAGATT GTCGGGGA), *c-Fos* (forward: CTCCTGAAGAGGAAGAGAAACG; reverse: GTGTATCTGTCAGCTCCCTCCT), *Lims2* I (forward: GTCAACAGCAATGGGGAACT; reverse: AGAAGAGTCCCTCGGGAAAT), *Lims2* II (forward: GCCAAGTGTGAGAAGCCATT; reverse: CAGACATCCCCAAAGAGCTG), *Lims2* III (forward: GTTCGATATGAAGCCCGTGT; reverse: CGGACAGCTTCTTCAACCTC), *Gpr17* (forward: GGATAGAGAAGCACCTCAAGAA; reverse: CACGGTAGTGAAGCACATAGA), Rat primers: *GAPDH* (forward: ACTCC CATTCTTCCACCTTTG; reverse: CCCTGTTGCTGTAGCCATATT), *AgRP* (forward: CTGTGTAAGGCTGCACGAGTC; reverse: AGG TATTGAAGAAGCGGCAGT), *POMC* (forward: TGCCGAGATTCTGCTACAGTC; reverse: CACCAGCTCCACACGTCTATG), *PDK1* (forward: GAACTGTTCAAGAACGCAATGA, reverse: CCAGTGTGACGTGAACTTGAAT).

### Western blotting analysis {#S29}

The hypothalamus was isolated from brain and then lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% deoxycholate, 0.1% SDS). The primary neurons were lysed in cell lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM NaF, 1 mM PMSF), supplemented with protease inhibitor cocktail (MCE Cat^\#^ HY-K0010), phosphatase inhibitor cocktail I (MCE Cat^\#^ HY-K0021), and phosphatase inhibitor cocktail II (MCE Cat^\#^ HY-K0022) on ice for 30 min followed by centrifugation at 12,000 rpm for 30 min. Protein concentrations were measured using the BCA Protein Assay Kit (Sangon Biotech Cat^\#^ C503021). Proteins were resolved on 12% SDS-PAGE and transferred to PVDF membrane (GE Healthcare Cat^\#^ 10600023). Membranes were blocked with 3% BSA in TBS (50 mM Tris-HCl, pH 7.5, 150 mM NaCl) for 1 h and then incubated overnight at 4°C with primary antibodies. After 3 washes with TBS plus 0.05% Tween 20, membranes were incubated with secondary antibodies for 1 h and developed using an ECL kit (Millipore Cat^\#^ WBKLS0500).

### Intracellular cAMP concentration assessment {#S30}

To assess intracellular cAMP concentration, primary mouse OPCs were cultured in poly-D-lysine-coated wells of 96-well plates at a density of 2 3 10^4^/well. cAMP was quantified using the cAMP-Glo Assay Kit (Promega Cat^\#^ V1501) following the manufacturer's instructions.

### Transfection and reporter gene assays {#S31}

293T cells in 24-well plates were transfected with either the pBOB-GFP or pBOB-c-Fos and co-transfected with luciferase reporter plasmid PGL3-PDK1 or the mutant plasmid with Lipofectamine 3000 (Thermo Fisher Scientific Cat^\#^ L3000--015). The *Renilla* lucif-erase construct pRL-TK (Promega Cat^\#^ E2241) was co-transfected as a normalization control. After 24 h, the cells were harvested and lysed, and 20 mL of each lysate was incubated with luciferase substrates for firefly and *Renilla* (Promega Cat^\#^ E151A). The PDK1-dependent firefly luciferase activity was normalized to *Renilla*-dependent luciferase activity.

### Lactate colorimetric assay {#S32}

To determine the lactate release, OPCs were seeded into 24-well plates at a density of 5 × 10^4^ cells/well and cultured until the desired stage in appropriate medium. The culture medium was first changed to 250 μL of glucose-free DMEM medium (GIBCO Cat^\#^ 11966025) to starve the cells for 1 h, then 25 mM D-glucose (Sigma Cat^\#^ G8270) was added into the medium to initiate glycolysis. For the hM4Di OPCs, 5 μM CNO was added at the beginning of glucose starvation. The medium was collected 1 h after glucose treatment and treated with two volumes of acetone immediately to precipitate protein. Samples were then lyophilized to remove acetone and re-dissolved in sterilized deionized water. For tissue lactate content detection, mouse brains were dissected, and the hypothalamus was snapfrozen in liquid nitrogen within 20 s. The isolated hypothalamus samples were weighed and homogenized in 50% methanol to precipitate protein. After centrifuging at 4°C, the homogenate was lyophilized and re-dissolved by sterilized deionized water. Lactate levels were measured using the L-lactate assay kit according to the manufacturer's protocol (Biovision Cat^\#^ K627--100).

### Cellular metabolism measurement {#S33}

Cellular glycolysis and oxidative phosphorylation were monitored with a Seahorse XFe96 extracellular flux analyzer (Seahorse Bioscience XFe96) by measuring the ECAR and OCR, respectively, in real time as described by the manufacturer. Briefly, 1.5 × 10^4^ to 2 × 10^4^ OPCs were seeded in specific 96-well plates designed for XF96 with appropriate growth medium. Prior to measurements, cells were washed three times with the XF base medium (Agilent, Cat^\#^ 102353) and incubated in the absence of CO~2~ at 37°C for 1 h in the XF base medium. The OCR and ECAR values were measured in a 9-min cycle of mix (3 min), dwell (3 min), and measure (3 min). The basal levels of OCR and ECAR were recorded first, and then the OCR and ECAR levels were recorded after sequential injection of compounds that inhibit the respiratory mitochondrial electron transport chain, ATP synthesis, or glycolysis as described previously ([@R38]).

### Stereotaxic microinjection {#S34}

Mice were starved for 16 h, followed by a 4 h refeeding before experiments, and then anesthetized by chloral hydrate (300 mg/kg, i.p.) and placed in a stereotactic device. A stainless-steel microliter syringe was inserted into the third ventricle (−1.7 mm posterior and 0 mm lateral to bregma, and −5.0 mm ventral from the dura), then 5 μL of vehicle (sterile saline), 5 or 10 mM lactate, 4 mM 4-CIN, or 20 mM oxamate was injected at a rate of 0.5 μL/min. When 4-CIN pretreatment was performed, 4-CIN or saline was administrated 1 h before the subsequent vehicle or lactate injection. The hypothalamus samples were collected and flash frozen by liquid nitrogen at indicated time points after injection. For food intake measurement after stereotaxic microinjection, mice were separately housed and fasted with water supply for 4h (9:00 to 13:00) before surgery, and then refed after injection. The remaining food pellets were weighed at 24 hr after surgery as described previously ([@R27]).

### Clozapine-N-oxide (CNO) treatment {#S35}

The *Gi-DREADD* or *Olig1*^*cre/+*^*;Gi-DREADD* mice at P12 were intraperitoneally injected with CNO (1 mg/kg) for 2 h, and then their hypothalamus samples were collected for total mRNA analysis or lactate colorimetric assay.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S36}
---------------------------------------

The statistical analyses are performed with Graphpad Prism 5. The data for two-group comparisons were analyzed for statistical significance using two-tailed Student's t tests. Error bars represent standard error of measurement (s.e.m.). For multiple comparisons, which were performed using one-way analyses of variance (ANOVAs), the Tukey's multiple-comparison test was used for post-tests. P values are indicated with single asterisk (\* \< 0.05), double asterisks (^\*\*^ \< 0.01) and triple asterisks (^\*\*\*^ \< 0.001) on graphs. The n number for each experiment has been stated in figure legends.

DATA AND SOFTWARE AVAILABILITY {#S37}
------------------------------

All data used in this manuscript are available upon request. The original data are available at <https://data.mendeley.com/datasets/wdmx6trhnr/4>
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![Gpr17^−/−^ Mice Are Resistant to HFD-Induced Obesity (A--H) *Gpr17*^−/−^ and their wild-type (WT) littermates were subjected to 28-week HFD feeding initiating at 4 weeks of age. After feeding, the mice were sacrificed, and tissue samples were collected.\
(A) Body weight recorded weekly.\
(B) Weight of eWAT.\
(C) Levels of serum insulin.\
(D) Levels of serum leptin.\
(E) Representative images of H&E stained eWAT, BAT, and liver. Scale bar, 50 μm.\
(F) The volume of the adipocytes in eWAT.\
(G) Lipid droplet-positive area in the BAT.\
(H) Triglyceride content in the liver.\
(I) Glucose tolerance test (GTT) at 24 weeks of HFD.\
(J) Insulin tolerance test (ITT) at 25 weeks of HFD.\
(K) The food intake of WT and *Gpr17*^−/−^ mice.\
(L--O) Metabolic parameters of *Gpr17*^−/−^ and WT mice after 26 weeks of HFD feeding, normalized by lean body mass. Shown are (L) O~2~ consumption, (M) CO~2~ production, (N) heat production, and (O) ambulatory activity recorded during 48 h of dark and light cycles.\
Open and filled bars represent light and dark phases, respectively. Each value represents mean ± SEM of 7 mice from each genotype. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, Student's t test.](nihms-1041717-f0002){#F1}

![**Gpr17 Is Expressed Predominantly in the Oligodendrocyte Lineage** (A) Immunofluorescent analysis of GFP, Olig2, and NeuN in cryostat sections of the corpus callosum (C.C), arcuate nucleus (ARC), and ventromedial nucleus (VMH) of *Gpr17*^−/−^ mice as described in [STAR Methods](#S14){ref-type="sec"}. Scale bar, 25 μm. The percentage of Olig2- or NeuN-positive cells was quantified as indicated. N.D., not detected.\
(B) Immunofluorescence analysis of GFP and AgRP or POMC in the ARC of *Gpr17*^−/−^ mice. Scale bar, 25 μm. Arrows indicate GFP-positive cells.\
(C) Immunofluorescence analysis of tdTomato and oligodendrocyte lineage markers, including Olig2, CC1, and PDGFRα, and the neuron marker NeuN in cryostat sections from the C.C (Olig2, CC1, and PDGFRα) or ARC (NeuN) in *Olig1*^*cre/+*^;*tdTomato* mice. Scale bar, 25 μm. Arrows indicate tdTomato-positive cells. The percentages of Olig2-, CC1-, PDGFRα-, and NeuN-positive cells were quantified as indicated.\
(D) Immunofluorescence analysis of tdTomato and AgRP or POMC in the ARC of *Olig1*^*cre/+*^;*tdTomato* mice. Scale bar, 25 mm. Arrows indicate tdTomato-positive cells.](nihms-1041717-f0003){#F2}

![Loss of Oligodendrocytic GPR17 Protects against HFD-Induced Obesity (A--H) *Gpr17cKO* (*Olig1*^*cre/+*^*;Gpr17*^*fl/fl*^) and control (*Gpr17*^*fl/fl*^) mice were subjected to HFD feeding initiated at 8 weeks of age. The mice were sacrificed, and tissue samples were collected after 30 weeks on the HFD.\
(A) Body weight recorded weekly.\
(B) Weight of eWAT.\
(C) Serum levels of insulin.\
(D) Serum levels of leptin.\
(E) Representative images of H&E stained eWAT, BAT, and liver. Scale bar, 50 μm.\
(F) The volume of the adipocytes in eWAT.\
(G) Lipid droplet-positive area in the BAT.\
(H) Triglyceride content in the liver.\
(I) GTT at 24 weeks of HFD.\
(J) ITT at 25 weeks of HFD.\
(K) The food intake of control and *Gpr17cKO* mice.\
(L--O) Metabolic parameters of *Gpr17cKO* and WT mice after 26 weeks of HFD feeding, normalized by lean body mass. Shown are (L) O~2~ consumption, (M) CO~2~ production, (N) heat production, and (O) ambulatory activity during 48 h of dark and light cycles.\
Open and filled bars represent light and dark phases, respectively. Each value represents mean ± SEM of 11 mice per genotype. \*p \< 0.05, ^\*\*^p \< 0.01, ^\*\*\*^p \< 0.001, Student's t test.](nihms-1041717-f0004){#F3}

![**Ablation of Gpr17 Promotes Glycolysis in Oligodendrocytes** Primary OPCs from WT or *Gpr17*^−/−^ mice were isolated, cultured, and differentiated into oligodendrocytes (OLs) as described in the [STAR Methods](#S14){ref-type="sec"}.\
(A) ECAR of WT and *Gpr17*^−/−^ OPCs as a function of time after sequential administrations of 10 mM glucose, 1.5 μM oligomycin, and 50 mM 2-Deoxy-D-glucose (2-DG). Dotted lines indicate the starting point of treatment with the indicated compounds.\
(B) Quantifications of the ECAR results in (A).\
(C) Lactate concentration in the medium of WT and *Gpr17*^−/−^ OPCs.\
(D) ECAR of WT and *Gpr17*^−/−^ OLs.\
(E) Quantifications of the ECAR results in (D).\
(F) Lactate concentrations in the culture medium of WT and *Gpr17*^−/−^ OLs.\
(G and H) OCR was monitored over time after sequential administration of 1.5 μM oligomycin, 1.5 μM carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), and 0.5 mM rotenone and antimycin A mixture in (G) OPCs and (H) OLs.\
(I) Viability of mouse OPCs measured with the CCK-8 assay.\
Data are means of at least three independent experiments. Each value represents mean ± SEM. \*p \< 0.05, ^\*\*^p \< 0.01, ^\*\*\*^p \< 0.001, Student's t test.](nihms-1041717-f0005){#F4}

![**Ablation of Gpr17 Increases Pdk1 Expression through cAMP-PKA Signaling** (A) Total proteins isolated from primary OPCs and OLs from WT or *Gpr17*^−/−^ mice were subjected to western blot using the indicated antibodies. The relative band intensity of each protein is shown on the right. The experiments were repeated 3 times.\
(B) Total RNAs were isolated, and *Pdk1* was quantified by real-time PCR. n = 3 animals/genotype.\
(C) Total protein was extracted from the hypothalamus of *Gpr17*^*fl/fl*^ and *Gpr17cKO* mice fed the NCD or HFD for 30 weeks and subjected to western blot using the indicated antibodies. The relative intensity of each band is shown on the right panel. n = 3 animals/genotype.\
(D) Intracellular cAMP levels in OPCs and OLs from WT or *Gpr17*^−/−^ mice.\
(E--J) ECAR after sequential administration of 10 mM glucose, 1.5 μM oligomycin, and 50 mM 2-DG of (E) WT OPCs treated with 0.5 mM dibutyl-cAMP (db-cAMP),(F) WT OPCs treated with 10 mM forskolin (FSK), (G) *Gpr17*^−/−^ OPCs treated with 0.5 μM KT5720, (H) WT OLs treated with 0.5 mM db-cAMP, (I) WT OLs treated with 10 μM FSK, and (J) *Gpr17*^−/−^ OLs treated with 0.5 μM KT5720. Dotted lines indicate the starting point of treatment with the indicated compounds.\
(K) Total RNAs were isolated, and *c-Fos* was quantified detected by real-time PCR as described in the [STAR Methods](#S14){ref-type="sec"}.\
(L) Total proteins isolated from primary OPCs and OLs from WT or *Gpr17*^−/−^ mice were subjected to western blot using the indicated antibodies. The relative band intensity of each protein is shown on the right. n = 3 animals/genotype.\
(M) OLN-93 cells were transfected with an empty vector (Vec) or the *c-Fos*-expressing construct pBOB-c-Fos (c-Fos) for 48 h. Total mRNA was harvested, and *Pdk1* mRNA was quantified by real-time PCR.\
(N) HEK293T cells were co-transfected with empty Vec or pBOB-c-Fos and the *Pdk1* promoter constructs containing a WT or mutated c-Fos response element. Luciferase activities were assayed 24 h after transfection.\
Data were reproduced from at least three independent experiments. Each value represents mean ± SEM. \*p \< 0.05, ^\*\*^p \< 0.01, ^\*\*\*^p \< 0.001, Student's t test.](nihms-1041717-f0006){#F5}

![Hypothalamic Administration of Lactate Modulates Appetite through Activation of AKT and STAT3 Signaling (A) Primary hypothalamus neurons were treated with 20 mM lactate. Left: levels of phosphorylated AKT (p-AKT) and phosphorylated STAT3 (p-STAT3) were analyzed by western blotting. Right: Relative intensities of p-AKT or p-STAT3 normalized to total AKT or STAT3. n = 3 independent experiments.\
(B) Neurons were pretreated with 0.25 mM 4-CIN for 15 min and then treated with 20 mM lactate for 15 min. Left: the levels of p-AKT and p-STAT3 were analyzed by western blotting. Right: relative intensities of p-AKT or pSTAT3 normalized to total AKT or STAT3. n = 3 independent experiments.\
(C) The relative mRNA levels of *Pomc* and *Agrp* were measured by real-time qPCR in neurons treated with 0 (−) or 20 mM (+) lactate for 1 h with or without a 15-min pretreatment with 0.25 mM 4-CIN.(D and E) WT 8-week-old mice received i.c.v. microinjections of 50 nmol lactate (D) and were sacrificed after the indicated time or (E) received the indicated dose of lactate and were sacrificed after 120 min. Left: total hypothalamic proteins were extracted and subjected to western blot using the indicated antibodies. Right: relative intensities of p-AKT or p-STAT3 normalized to total AKT or STAT3. n = 3 independent experiments.(F) WT 8-week-old mice received i.c.v. microinjections of saline or 25 or 50 nmol of lactate. Hypothalamus samples were collected 6 h after the injections. The relative mRNA levels of *Pomc* and *Agrp* were measured by real-time qPCR. (G and H) Mice were injected i.c.v. with 50 nmol of lactate with or without a 1-h pretreatment with 40 nmol 4-CIN.\
(G) Left: mice were sacrificed 2 h after injection of lactate, and hypothalamus samples were subjected to western blot using the indicated antibodies. Right: relative intensities of p-AKT or p-STAT3 normalized to total AKT or STAT3. n = 3 independent experiments.\
(H) Mice (n = 6/group) were subjected to 24-h food intake measurement.\
Each value represents mean ± SEM from three independent experiments. \*p \< 0.05, ^\*\*\*^p \< 0.001, Student's t test.](nihms-1041717-f0007){#F6}

![**Depletion of Gpr17 or Activation of OLs Regulates AgRP and POMC Neuron Activity** (A) Lactate was quantified in hypothalamus samples from *Gpr17*^*fl/fl*^ (control \[Ctrl\]) and *Gpr17cKO* mice subjected to either NCD or HFD feeding for 30 weeks (n = 6 animals/genotype).\
(B) Left: hypothalamus samples from mice fed the NCD were analyzed by western blot using the indicated antibodies. Right: relative intensities of p-AKT or p-STAT3 normalized to total AKT or STAT3. n = 3 animals/genotype.\
(C) Left: hypothalamus samples from mice fed the HCD were analyzed by western blot using the indicated antibodies. Right: relative intensities of p-AKT or p-STAT3 normalized to total AKT or STAT3. n = 3 animals/genotype.\
(D) Left: immunofluorescent staining for p-AKT or p-STAT3 of cryostat sections from representative hypothalamus samples of *Gpr17*^*fl/fl*^ and *Gpr17cKO* mice after 30 weeks of HFD feeding. Scale bar, 50 μm. Right: quantification of samples from 3 mice.\
(E) NCD-fed *Gpr17cKO* mice were injected i.c.v. with 4-CIN or oxamate (Oxa). Left: after 12 h, total protein samples were collected from the hypothalamus and subjected to western blot using the indicated antibodies. Right: the relative band intensity of each protein. n = 3 animals/group.\
(F) After 30 weeks of HFD feeding, the levels of *Pomc* and *Agrp* in the hypothalamus of *Gpr17*^*fl/fl*^ and *Gpr17cKO* mice were measured by real-time qPCR (n = 9 animals/genotype).\
(G) Immunofluorescent staining for POMC and c-Fos in the hypothalamus of *Gpr17*^*fl/fl*^ and *Gpr17cKO* mice after 30 weeks of HFD. Scale bar, 25 μm.(H and J) Lactate content (H) and mRNA (J) levels of *Pomc* and *Agrp* in the hypothalamus of *Gi-DREADD* or *Olig1*^*cre/+*^*;Gi-DREADD* mice treated with CNO (1 mg/kg) at P12 for 2 h (n = 5 animals/genotype).\
(I) Relative lactate content of isolated OPCs from *Gi-DREADD* or *Olig1*^*cre/+*^*;Gi-DREADD* mice with CNO treatment (5 μM) for 2 h (n = 3 independent experiments). Each value represents mean ± SEM from three independent experiments.\
All quantifications of immunofluorescent staining were obtained from at least nine images from three mice. Each value represents mean ± SEM. \*p \< 0.05, ^\*\*^p \< 0.01, Student's t test.](nihms-1041717-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                           SOURCE                                                   IDENTIFIER
  ------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Antibodies                                                                                                             
  Olig2                                                         Millipore                                                Cat^\#^ AB9610; RRID:AB_570666
  CC1                                                           Calbiochem                                               Cat^\#^ OP80; RRID:AB_2057371
  PDGFRα                                                        Santa Cruz Biotechnology                                 Cat^\#^ SC-338; RRID:AB_631064
  GFAP                                                          Cell Signaling Technology                                Cat^\#^ 3670; RRID:AB_561049
  Iba-1                                                         Wako                                                     Cat^\#^ 019--19744; RRID: AB_839504
  NeuN                                                          Abcam                                                    Cat^\#^ Ab177487; RRID:AB_2532109
  c-Fos                                                         Abcam                                                    Cat^\#^ Ab7693; RRID: AB_306177
  phosphorylated PKA                                            Santa Cruz Biotechnology                                 Cat^\#^ SC-32968; RRID:AB_2237593
  PKA                                                           Santa Cruz Biotechnology                                 Cat^\#^ SC-98951; RRID:AB_2170328
  GAPDH                                                         Proteintech                                              Cat^\#^ 60004--1-lg; RRID: AB_2107436
  POMC                                                          Phoenix Pharmaceuticals                                  Cat^\#^ H-029--30; RRID:AB_2307442
  AGRP                                                          R&D Systems                                              Cat^\#^ AF634; RRID:AB_2273824
  phosphorylated STAT3                                          Cell Signaling Technology                                Cat^\#^ 9131; RRID:AB_331586
  STAT3                                                         Cell Signaling Technology                                Cat^\#^ 12640; RRID:AB_2629499
  phosphorylated AKT                                            Cell Signaling Technology                                Cat^\#^ 4060; RRID:AB_2315049
  AKT                                                           Cell Signaling Technology                                Cat^\#^ 9272; RRID:AB_329827
  PDK1                                                          Cell Signaling Technology                                Cat^\#^ 3820; RRID:AB_1904078
  phosphorylated PDH                                            Abcam                                                    Cat^\#^ ab177461; RRID:AB_2756339
  PDH                                                           Cell Signaling Technology                                Cat^\#^ 3205; RRID:AB_2162926
  MBP                                                           Biolegend                                                Cat^\#^ 808401; RRID:AB_2564741
  NG2                                                           Millipore                                                Cat^\#^ AB5320; AB_11213678
  Parvalbumin                                                   Abcam                                                    Cat^\#^ ab11427; RRID:AB_298032
  Critical Commercial Assays                                                                                             
  cAMP-Glo Assay Kit                                            Promega                                                  Cat^\#^ V1501
  L-lactate assay kit                                           Biovision                                                Cat^\#^ K627--100
  Deposited Data                                                                                                         
  Original pictures                                             This paper                                               DOI: <https://data.mendeley.com/datasets/wdmx6trhnr/4>
  Experimental Models: Organisms/Strains                                                                                 
  *Gt(ROSA)26Sor*^*tm1(CAG-CHRM4*\*,-*mCitrine)Ute*^*/J* mice   Jackson laboratory                                       Cat^\#^ 026219
  *Gt(ROSA)26Sor*^*tm9(CAG-tdTomtao)Hze*^ mice                  Kindly provided by Dr. Liang Zhang (Xiamen University)   N/A
  *Gpr17*^−/−^ mice                                             [@R5]                                                    N/A
  *Olig1*^*cre/+*^*;Gpr17*^*fl/fl*^ mice                        [@R28]                                                   N/A
  C57BL/6 mice                                                  Xiamen University Laboratory Animal Center               N/A
  Sprague-Dawley rats                                           Xiamen University Laboratory Animal Center               N/A

###### Highlights

-   GPR17-deficient mice are resistant to high-fat-diet-induced obesity

-   Oligodendrocytic Gpr17 signaling controls metabolic homeostasis and food intake

-   Oligodendrocyte lactate is a metabolic signal for neuronal AKT/STAT3 signaling

-   Oligodendrocytic GPR17-cAMP-lactate axis regulates neuronal activity
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